培美曲塞联合奈达铂治疗晚期非小细胞肺癌的临床疗效  

Clinical effects of pemetrexed combine with nedaplatin in advanced non-small cell lung cancer

作　　者：李冬杰[1] 李冬雷[1] 李润浦 

机构地区：[1]河北省保定市第二中心医院肿瘤科,保定072750

出　　处：《中国肿瘤临床与康复》2015年第4期425-427,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨培美曲塞和奈达铂治疗晚期非小细胞肺癌(NSCLC)的临床效果。方法按照随机数字表法将2011年7月至2013年7月间收治的88例晚期NSCLC患者分为研究组和对照组,每组44例。研究组患者采用培美曲塞联合奈达铂治疗,对照组患者采用吉西他滨联合奈达铂治疗,比较两组患者疗程结束后的近期疗效、治疗期间不良反应发生情况以及中位生存时间、无进展生存时间和1年生存率。结果两组患者近期疗效的差异无统计学意义(P>0.05)。研究组患者治疗期间不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。研究组患者中位生存期明显长于对照组,差异有统计学意义(P<0.05)。两组患者无进展生存期及1年生存率比较,差异无统计学意义(P>0.05)。结论培美曲塞联合奈达铂治疗晚期NSCLC,疗效显著,患者均可耐受不良反应,值得临床推广。Objective To explore the clinical effects of pemetrexed combine with nedaplatin in advanced non-small cell lung cancer（ NSCLC）. Methods A total of 88 cases of patients with advanced NSCLC were randomly divided into research group and control group. The research group were treated by pemetrexed combine with nedaplatin,the control group were treated by gemcitabine combine with nedaplatin. The clinical effects,adverse reactions and mean survival,progression free survival,one year survival rate were compared for the two groups. Results There was no significant difference on the short term effect for the two groups（ P〈0. 05）; The adverse reactions for the research group were lower than the control group（ P〉0. 05）; The mean survival for the research group were better than the control group（ P〈0. 05）; There was no significant difference on the progression free survival and 1-yr survival rate（ P〉0. 05）. Conclusion The clinical effects of advanced NSCLC by pemetrexed combine with nedaplatin is good. It has significant effect,adverse reactions tolerable,and is worthy of clinical promotion.

关 键 词：肺肿瘤 培美曲塞 奈达铂 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]